San Diego-based Viking Therapeutics marked alone as a serious competitor during the weight loss drug industry in February following revealing promising knowledge from a mid-phase demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection and in March the company unveile